236. Pseudohypoparathyroidism Clinical trials / Disease details

Clinical trials : 3 / Drugs : 3 - (DrugBank : 2) / Drug target genes : 18 - Drug target pathways : 23

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04551170 (ClinicalTrials.gov)	July 13, 2020	9/9/2020	Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism	Pseudohypoparathyroidism;Albright Hereditary Osteodystrophy;Pseudohypoparathyroidism Type 1a	Drug: Theophylline;Drug: Placebo	Vanderbilt University Medical Center	NULL	Recruiting	2 Years	12 Years	All	34	Phase 2	United States
2	NCT02463409 (ClinicalTrials.gov)	June 2015	20/5/2015	Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)	Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1a	Pseudohypoparathyroidism Type 1a;Albright Hereditary Osteodystrophy	Drug: Theophylline	Vanderbilt University Medical Center	Massachusetts General Hospital	Completed	10 Years	21 Years	All	6	Phase 2	United States
3	NCT00497484 (ClinicalTrials.gov)	February 1995	5/7/2007	Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)	Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)	Pseudohypoparathyroidism;Growth Hormone Deficiency, Dwarfism	Drug: recombinant human somatotropin	University of Milan	Eli Lilly and Company	Active, not recruiting	1 Year	18 Years	Both		N/A	Italy